One Eye BlindnessNCT06024668
Simulated Walking With Multiplexing Prism for Field Expansion in Monocular Vision
A study testing Multiplexing Prism in people with One Eye Blindness and Blind Left Eye, run by Massachusetts Eye and Ear Infirmary at 1 site in United States.
Trial summary
The investigators are developing an assistive device, known as multiplexing prism that expands the field of view for individuals with acquired monocular vision (loss of an eye). The investigators will test the efficacy of the prism in improving the detection of colliding pedestrians during a simulated walking task. Read more about this study
- Who is it for?
- Ages 16 years and older
- Conditions the study is for
- One Eye Blindness, Blind Left Eye, Blind Right Eye
- What is being tested?
- Multiplexing Prism
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- 1 siteUnited States
- Study dates
- 4 Aug 2024to 1 Jan 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- No medical health issues such as seizures, motor movements problem
- Loss of vision in one eye (less than 20/200) for >1 year
- Visual acuity of the seeing eye: Better than 20/32 visual acuity with correction
- No visual field defect in the seeing eye (nasal field of at least >45degree)
Who cannot join
- Patients with any physical or mental disabilities, including cognitive dysfunction, balance problems, or other deficits that could impair their ability to respond to the stimuli presented in this study will be excluded
- Any person with a history (such as pacemaker use or photosensitive epilepsy)
- Any person with motor movements problem (e.g., unable to use extremities)
Trial locations and contacts
1 site in 1 country.
United States1 site
Schepens Eye Research Institute
Boston, Massachusetts, 02114
About this study
Official title: Monocular Visual Confusion for Field Expansion
The investigators are developing an assistive device, known as multiplexing prism that expands the field of view for individuals with acquired monocular vision (loss of an eye). The investigators will test the efficacy of the prism in improving the detection of colliding pedestrians during a simulated walking task.
- Conditions
- One Eye Blindness, Blind Left Eye, Blind Right Eye
- Being tested
- Multiplexing Prism
- Keywords
- Simulated Walking, Collision, Field Expansion, One eye blindness
- Medical subject headings
- Blindness
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Multiplexing PrismDevice
Multiplexing prism is designed for spatial vision multiplexing. It allows partial light transmission through the prism allow the observer to simultaneously see the physical world through the prism and see the "shifted view" from the non-seeing side. It is developed to expand the field of view of individuals with just one eye.
| Study group | Role | What they receive |
|---|---|---|
| Detection of colliding pedestrian | Experimental | Participants will perform a simulated walking task in which surrounding pedestrians will walk towards and make a collision. Participants will respond by pressing buttons to indicate the direction of the colliding pedestrians. Participants will perform the task with and without the multiplexing prism in random orders. Receives: Device: Multiplexing Prism |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean response time to detect colliding pedestrian
The investigators will compare the mean response time to detect colliding pedestrians coming from the nasal (same side as the blind eye) and temporal (same side as the seeing eye) visual field with and without multiplexing prism. The comparison will be made between these four: Nasal without prism, Temporal without prism, Nasal with prism, and Temporal with prism.
Measured: Approximately 3 sessions, up to 3 hours for each session, any time within 4 month period
Secondary outcomes (1)
Pedestrian Detection Rate
The investigators will measure the rate of correct detection rate of colliding pedestrians in the nasal (same side as the blind eye) and temporal (same side as the seeing eye) with and without multiplexing prism. Comparisons will be made for these: nasal without prism, temporal without prism, nasal with prism,and temporal with prism.
Measured: Approximately 3 sessions, up to 3 hours for each session, any time within 4 month period
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Sep 2023
- Study start4 Aug 2024
- Primary completion31 Dec 2024
- Study completion1 Jan 2025
Why it stopped: Investigators left the research institute.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for One Eye BlindnessStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Individuals with Acquired Monocular Vision/ Blindness in One Eye
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Sponsor type
- University, hospital or other
- Collaborators
- National Eye Institute (NEI)
- Responsible party
- Principal investigator, Eli Peli, Massachusetts Eye and Ear Infirmary
- Investigators
- Eli Peli, OD, Principal investigator, Schepens Eye Research Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06024668
- Sponsor's protocol ID
- 2023P001885
- Other IDs
- R01EY031777
- Status last verified
- Jul 2026
- First submitted
- 29 Aug 2023
- Last updated
- 9 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Jung JH, Castle R, Kurukuti NM, Manda S, Peli E. Field Expansion with Multiplexing Prism Glasses Improves Pedestrian Detection for Acquired Monocular Vision. Transl Vis Sci Technol. 2020 Jul 23;9(8):35. doi: 10.1167/tvst.9.8.35. eCollection 2020 Jul.
PubMed 32855881Jung JH, Peli E. Field Expansion for Acquired Monocular Vision Using a Multiplexing Prism. Optom Vis Sci. 2018 Sep;95(9):814-828. doi: 10.1097/OPX.0000000000001277.
PubMed 30169357Jung JH, Peli E. No Useful Field Expansion with Full-field Prisms. Optom Vis Sci. 2018 Sep;95(9):805-813. doi: 10.1097/OPX.0000000000001271.
PubMed 30169356
Study at a glance
From the registry record, last updated by the sponsor on 9 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Monocular Visual Confusion for Field Expansion
- ClinicalTrials.gov ID
- NCT06024668
- Acronym / sponsor ID
- 2023P001885
- Conditions
- One Eye Blindness, Blind Left Eye, Blind Right Eye
- Keywords
- Simulated Walking, Collision, Field Expansion, One eye blindness
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: Investigators left the research institute.
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Massachusetts Eye and Ear InfirmaryUniversity, hospital or other
- Collaborators
- National Eye Institute (NEI)
- Study start
- 4 Aug 2024 (actual)
- Primary completion
- 31 Dec 2024 (actual)
- Study completion
- 1 Jan 2025 (actual)
- First posted
- 6 Sep 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The investigators are developing an assistive device, known as multiplexing prism that expands the field of view for individuals with acquired monocular vision (loss of an eye). The investigators will test the efficacy of the prism in improving the detection of colliding pedestrians during a simulated walking task.
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Individuals with Acquired Monocular Vision/ Blindness in One Eye
| Arm | Type | Receives |
|---|---|---|
| Detection of colliding pedestrian | Experimental | Device: Multiplexing PrismParticipants will perform a simulated walking task in which surrounding pedestrians will walk towards and make a collision. Participants will respond by pressing buttons to indicate the direction of the colliding pedestrians. Participants will perform the task with and without the multiplexing prism in random orders. |
Who may qualify
- Ages
- 16 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (4 listed)
- No medical health issues such as seizures, motor movements problem
- Loss of vision in one eye (less than 20/200) for >1 year
- Visual acuity of the seeing eye: Better than 20/32 visual acuity with correction
- No visual field defect in the seeing eye (nasal field of at least >45degree)
Key exclusion criteria (3 listed)
- Patients with any physical or mental disabilities, including cognitive dysfunction, balance problems, or other deficits that could impair their ability to respond to the stimuli presented in this study will be excluded
- Any person with a history (such as pacemaker use or photosensitive epilepsy)
- Any person with motor movements problem (e.g., unable to use extremities)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Multiplexing PrismMultiplexing prism is designed for spatial vision multiplexing. It allows partial light transmission through the prism allow the observer to simultaneously see the physical world through the prism and see the "shifted view" from the non-seeing side. It is developed to expand the field of view of individuals with just one eye. | Device | Detection of colliding pedestrian |
Primary outcome
Mean response time to detect colliding pedestrian
Time frame: Approximately 3 sessions, up to 3 hours for each session, any time within 4 month period
The investigators will compare the mean response time to detect colliding pedestrians coming from the nasal (same side as the blind eye) and temporal (same side as the seeing eye) visual field with and without multiplexing prism. The comparison will be made between these four: Nasal without prism, Temporal without prism, Nasal with prism, and Temporal with prism.
1 secondary outcome
Pedestrian Detection Rate
Time frame: Approximately 3 sessions, up to 3 hours for each session, any time within 4 month period
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jul 2026.
- Results publication: PubMed 32855881Jung JH, Castle R, Kurukuti NM, Manda S, Peli E. Field Expansion with Multiplexing Prism Glasses Improves Pedestrian Detection for Acquired Monocular Vision. Transl Vis Sci Technol. 2020 Jul 23;9(8):35. doi: 10.1167/tvst.9.8.35. eCollection 2020 Jul.
- Results publication: PubMed 30169357Jung JH, Peli E. Field Expansion for Acquired Monocular Vision Using a Multiplexing Prism. Optom Vis Sci. 2018 Sep;95(9):814-828. doi: 10.1097/OPX.0000000000001277.
- Results publication: PubMed 30169356Jung JH, Peli E. No Useful Field Expansion with Full-field Prisms. Optom Vis Sci. 2018 Sep;95(9):805-813. doi: 10.1097/OPX.0000000000001271.
- Individual participant dataSharing planned: No
Related trials for One Eye Blindness
Not yet recruiting
Health Education vs Meditation in Irreversible Age-Related Vision Loss Patients and Their Caregivers
Low Vision, One Eye, Unspecified Eye, Low Vision Blindness
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Eli Peli, OD principal investigator
Schepens Eye Research Institute
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Multiplexing Prism in people with One Eye Blindness and Blind Left Eye, run by Massachusetts Eye and Ear Infirmary at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 9 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean response time to detect colliding pedestrian (time frame: Approximately 3 sessions, up to 3 hours for each session, any time within 4 month period). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06024668, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jul 2026.